BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Altor BioScience Corporation Licenses T-cell Receptors Targeting HIV and Hepatitis C from Massachusetts General Hospital


9/10/2008 8:55:20 AM

MIRAMAR, Fla.--(BUSINESS WIRE)--Altor BioScience Corporation (Altor) today announced that it has entered into an agreement with Massachusetts General Hospital (MGH) for exclusive, worldwide rights to develop and commercialize T-cell receptors (TCRs) specific for cells infected by HIV and Hepatitis C Virus (HCV). The license has resulted from the success of Altor’s collaboration established in 2004 with Howard Hughes Medical Institute and the Partners AIDS Research Center at MGH. Altor has already successfully improved and converted the licensed TCRs into targeted therapeutic reagents using its Soluble T-cell Antigen Receptor (STAR™) technology.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES